Roche Holding AG (RHHBY)
OTCMKTS · Delayed Price · Currency is USD
61.27
+0.50 (0.82%)
At close: Oct 30, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or 0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$754,676
Profits / Employee
$147,929
Market Cap
391.17B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Veradigm | 2,300 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Elite Pharmaceuticals | 65 |
| CytoDyn | 14 |
Roche Holding AG News
- 3 days ago - Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma - GlobeNewsWire
- 4 days ago - Roche receives CE Mark for cobas smart e immunoanalyser - TheFly
- 4 days ago - Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories - GlobeNewsWire
- 6 days ago - Roche Targets Emerging Oncology Market With New Lung-Cancer Drug - WSJ
- 6 days ago - Genentech says Phase III Krascendo 1 study met primary, secondary endpoints - TheFly
- 6 days ago - Roche says divarasib cut risk of death 44% in lung cancer trial - Reuters
- 6 days ago - Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer - Business Wire
- 6 days ago - Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer - GlobeNewsWire